, Volume 46, Issue 2, pp 279–284 | Cite as

Decrease in TSH levels after lactose restriction in Hashimoto’s thyroiditis patients with lactose intolerance

  • Mehmet Asik
  • Fahri Gunes
  • Emine Binnetoglu
  • Mustafa Eroglu
  • Neslihan Bozkurt
  • Hacer Sen
  • Erdem Akbal
  • Coskun Bakar
  • Yavuz Beyazit
  • Kubilay Ukinc
Original Article


We aimed to evaluate the prevalence of lactose intolerance (LI) in patients with Hashimoto’s thyroiditis (HT) and the effects of lactose restriction on thyroid function in these patients. Eighty-three HT patients taking l-thyroxine (LT4) were enrolled, and lactose tolerance tests were performed on all patients. Lactose intolerance was diagnosed in 75.9 % of the patients with HT. Thirty-eight patients with LI were started on a lactose-restricted diet for 8 weeks. Thirty-eight patients with LI (30 euthyroid and 8 with subclinical hypothyroidism), and 12 patients without LI were included in the final analysis. The level of TSH significantly decreased in the euthyroid and subclinical hypothyroid patients with LI [from 2.06 ± 1.02 to 1.51 ± 1.1 IU/mL and from 5.45 ± 0.74 to 2.25 ± 1.88 IU/mL, respectively (both P < 0.05)]. However, the level of TSH in patients without LI did not change significantly over the 8 weeks (P > 0.05). Lactose intolerance occurs at a high frequency in HT patients. Lactose restriction leads to decreased levels of TSH, and LI should be considered in hypothyroid patients who require increasing LT4 doses, have irregular TSH levels and are resistant to LT4 treatment.


Lactose intolerance Hashimoto’s thyroiditis Hypothyroidism l-Thyroxine malabsorption 


Conflict of interest

The authors have nothing to disclose.


  1. 1.
    M. Ruchała, E. Szczepanek-Parulska, A. Zybek, The influence of lactose intolerance and other gastro-intestinal tract disorders on L-thyroxine absorption. Endocrinol. Pol. 63, 318–323 (2012)Google Scholar
  2. 2.
    M. Centanni, Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches. Endocrine 43, 8–9 (2013)PubMedCrossRefGoogle Scholar
  3. 3.
    E. Vermeire, H. Hearnshaw, P. Van Royen, J. Denekens, Patient adherence to treatment: three decades of research. A comprehensive review. J. Clin. Pharm. Ther. 26, 331–342 (2001)PubMedCrossRefGoogle Scholar
  4. 4.
    T.G. Bach-Huynh, B. Nayak, J. Loh, S. Soldin, J. Jonklaas, Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94, 3905–3912 (2009)PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    P. Colucci, C.S. Yue, M. Ducharme, S. Benvenga, A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur. Endocrinol. 9, 40–47 (2013)Google Scholar
  6. 6.
    S. Benvenga, L. Bartolone, M.A. Pappalardo, A. Russo, D. Lapa, G. Giorgianni, G. Saraceno, F. Trimarchi, Altered intestinal absorption of l-thyroxine caused by coffee. Thyroid 18, 293–301 (2008)PubMedCrossRefGoogle Scholar
  7. 7.
    J.J. Lilja, K. Laitinen, P.J. Neuvonen, Effects of grapefruit juice on the absorption of levothyroxine. Br. J. Clin. Pharmacol. 60, 337–341 (2005)PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    L. Liwanpo, J.M. Hershman, Conditions and drugs interfering with thyroxine absorption. Best Pract. Res. Clin. Endocrinol. Metab. 23, 781–792 (2009)PubMedCrossRefGoogle Scholar
  9. 9.
    C. Virili, G. Bassotti, M.G. Santaguida, R. Iuorio, S.C. Del Duca, V. Mercuri, A. Picarelli, P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97, 419–422 (2012)CrossRefGoogle Scholar
  10. 10.
    P. Puri, E.J. Guiney, Transient hypothyroidism associated with short gut syndrome. J. Pediatr. Surg. 17, 22–24 (1982)PubMedCrossRefGoogle Scholar
  11. 11.
    M. Muñoz-Torres, M. Varsavsky, G. Alonso, Lactose intolerance revealed by severe resistance to treatment with levothyroxine. Thyroid 16, 1171–1173 (2006)PubMedCrossRefGoogle Scholar
  12. 12.
    N.S. Scrimshaw, E.B. Murray, Prevalence of lactose maldigestion. Am. J. Clin. Nutr. 48, 1086–1098 (1988)Google Scholar
  13. 13.
    E. Tuncbilek, R. Türün, B. Say, Lactose intolerance in Turkey. Lancet 2, 151 (1973)PubMedCrossRefGoogle Scholar
  14. 14.
    S.J. Mandel, G.A. Brent, P.R. Larsen, Levothyroxine therapy in patients with thyroid disease. Ann. Intern. Med. 119, 492–502 (1993)PubMedCrossRefGoogle Scholar
  15. 15.
    S. Ladas, J. Papanikos, G. Arapakis, Lactose malabsorption in Greek adults: correlation of small bowel transit time with the severity of lactose intolerance. Gut 23, 968–973 (1982)PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    H. Arola, Diagnosis of hypolactasia and lactose malabsorption. Scand. J. Gastroenterol. 29, 26–35 (1994)CrossRefGoogle Scholar
  17. 17.
    S.L. Carter, S. Attel, The diagnosis and management of patients with lactose-intolerance. Nurse Pract. 38, 23–28 (2013)PubMedCrossRefGoogle Scholar
  18. 18.
    S. Reichlin, R.D. Utiger, Regulation of the pituitary-thyroid axis in man: relationship of TSH concentration to concentration of free and total thyroxine in plasma. J. Clin. Endocrinol. Metab. 27, 251–255 (1967)PubMedCrossRefGoogle Scholar
  19. 19.
    M.B. Heyman, Lactose intolerance in infants, children, and adolescents. Pediatrics 118, 1279–1286 (2006)PubMedCrossRefGoogle Scholar
  20. 20.
    C.L. Ch’ng, M.K. Jones, J.G. Kingham, Celiac disease and autoimmune thyroid disease. Clin. Med. Res. 5, 184–192 (2007)PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    V. Ojetti, G. Nucera, A. Migneco, M. Gabrielli, C. Lauritano, S. Danese, M.A. Zocco, E.C. Nista, G. Cammarota, A. De Lorenzo, G. Gasbarrini, A. Gasbarrini, High prevalence of celiac disease in patients with lactose intolerance. Digestion 71, 106–110 (2005)PubMedCrossRefGoogle Scholar
  22. 22.
    P. Eadala, J.P. Waud, S.B. Matthews, J.T. Green, A.K. Campbell, Quantifying the ‘hidden’ lactose in drugs used for the treatment of gastrointestinal conditions. Aliment. Pharmacol. Ther. 29, 677–687 (2009)PubMedCrossRefGoogle Scholar
  23. 23.
    R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, A novel formulation of l-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 43, 154–160 (2013)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Mehmet Asik
    • 1
  • Fahri Gunes
    • 2
  • Emine Binnetoglu
    • 2
  • Mustafa Eroglu
    • 1
  • Neslihan Bozkurt
    • 2
  • Hacer Sen
    • 2
  • Erdem Akbal
    • 3
  • Coskun Bakar
    • 4
  • Yavuz Beyazit
    • 5
  • Kubilay Ukinc
    • 1
  1. 1.Department of Endocrinology and Metabolism, Faculty of MedicineÇanakkale Onsekiz Mart UniversityÇanakkaleTurkey
  2. 2.Department of General Medicine, Faculty of MedicineÇanakkale Onsekiz Mart UniversityÇanakkaleTurkey
  3. 3.Department of Gastroenterology, Faculty of MedicineÇanakkale Onsekiz Mart UniversityÇanakkaleTurkey
  4. 4.Department of Public Health, Faculty of MedicineÇanakkale Onsekiz Mart UniversityÇanakkaleTurkey
  5. 5.Department of GastroenterologyÇanakkale Government HospitalÇanakkaleTurkey

Personalised recommendations